dnak
The 70 kilodalton heat shock proteins are a family of conserved ubiquitously expressed heat shock proteins. Proteins with similar structure exist in virtually all living organisms and play crucial roles in the development of cancer, neurodegeneration, apoptosis, regulating sleep, and much more. Intracellularly localized Hsp70s are an important part of the cell's machinery for protein folding, performing chaperoning functions, and helping to protect cells from the adverse effects of physiological stresses. Additionally, membrane-bound Hsp70s have been identified as a potential target for cancer therapies and their extracellularly localized counterparts have been identified as having both membrane-bound and membrane-free structures. There is lot of potential in the Hsp70 protein as a key therapeutic target for developing new drugs for the treatment of sleep disorders, cancer, neurodegeneration, and other related pathological conditions. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2010 (NCT01111279)
Timeline
Indications
Mechanism of action
- Unspecified targetImmunity, desensitized
Immunity, desensitized
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01506375 | Phase 2 | Nov 1, 2011 | ASIT Biotech S.A. |
| NCT01111279 | Phase 1 | Mar 1, 2010 | ASIT Biotech S.A., Katholieke Universiteit Leuven |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ASIT Biotech S.A. | For profit | 2 | 2 | 2 | 2010 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2010 |